Park Ha Biological Technology Co., Ltd. (NASDAQ: BYAH) ('Park Ha Biological” or the 'Company”) announced that it has successfully passed the comprehensive and rigorous process to open a store on ...
(NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced an important enrollment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results